A biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates for global development
Debiopharm searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.
Milestones
The Company has successfully developed five products. These products include Eloxatin® for the treatment of colorectal cancer, Decapeptyl®/Trelstar®/Pamorelin® 1-month, 3-month and 6-month formulations for the treatment of advanced prostate cancer, endometriosis, precocious puberty, in vitro fertilisation programmes, uterine fibroids, and Moapar®/Salvacyl® for the treatment of severe sexual deviations.
Early 2010, Debiopharm licensed out a new product, Debio 025, for the treatment of
hepatitis C.
Management
 |
Bertrand DucreyChief Executive Officer, Debiopharm SA |
Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debio R.P. in 1995 as Pharmaceutical Project Manager. He then spent two years at Debiopharm S.A. as Innovative Formulation Manager. In 2004, he returned to Debio R.P. to head the company as Chief Executive Officer until 2011. Since 2012, Dr Ducrey heads Debiopharm SA as CEO.
 |
Andres McAllisterChief Scientific Officer, Research & Evaluation, Debiopharm SA |
Dr McAllister graduated from Medical School in 1985 in Bogota, Colombia and in 1991, obtained a Ph.D. in Molecular Virology from the Pasteur Institute in Paris, France. Previous job experiences include the Pasteur Institute in Paris; the University of California at San Francisco; the Centre d’Immunologie Pierre Fabre in France; and Director of R&D at Immune Design Molecules, a biotechnology company specialised in the immunotherapy of cancer. He joined Debiopharm SA in 2004.
 |
Jean-Maurice DumontVice President Medical Affairs, Debiopharm SA |
Dr Dumont received his Diploma of Pharmacy from the University of Lyon, France in 1978. He then obtained his certificate of specialisation in Pharmacodynamics and Pharmacokinetics, as well as his certificate of specialisation in Pharmaceutical Chemistry from the University of Lyon, France. Previous job experiences include Scientist in the Pharmaceutical Chemistry Department of the University of Lyon; Pharmacologist in the Research Department of Zyma SA (Novartis), Nyon, Switzerland where he headed the Hepatic and Gastro-enterology and then Biochemistry-Dermatology units; and Manager in Socar (Société pour la recherche en cardiologie) Research SA, Nyon, Switzerland, where he was responsible for the management of Multi-Centre Clinical trials in the field of Cardiology. He joined Debiopharm SA in 1998.
 |
Houssam IbrahimVice President Pharmaceutical Development, Debiopharm SA |
Dr Ibrahim received his Diploma of Pharmacy from the Faculty of Sciences of the University of Geneva, Switzerland in 1983, and in 1989, obtained his Ph.D. in Sciences from the ‘Laboratoire de Pharmacie Galénique’, University of Geneva. Dr Ibrahim has acquired international experience in the pharmaceutical industry, including quality assurance, regulatory affairs, pharmaceutical sciences and GMP productions for clinical trial materials and commercial products. Previous job experiences include work in Quality Assurance and Regulatory Affairs at Serono. He joined Debiopharm SA in 1992.
 |
Christine DeuschelVice President, Portfolio & Project Management, Debiopharm SA |
Dr Deuschel has been trained as chemist and received her Ph.D. in Science from the faculty of Sciences of the University of Fribourg, Switzerland in 1987. She later completed an MBA from HEC and EPFL, Lausanne, Switzerland, in 2007. Previous job experiences include post-graduate research at the University of California at Berkeley, Faculty member of the University of Bern, Switzerland. Dr Deuschel has also been Chief Operating Officer, and then Chief Executive Officer at Athelas SA Geneva, Switzerland, a start up company active in the fields of antibacterial drug-discovery, and Chief Scientific Officer at Anteis SA Geneva, Switzerland. She joined Debiopharm SA in 1995.
 |
Pierre KairouzDirector Human Resources, Debiopharm Group™ |
Mr Kairouz graduated in Engineering from the Swiss Federal Institute of Technology (EPFL) in 1986. Since then, he has acquired a broad international business and human resources experience in industrial multinational companies and consulting firms, such as Caterpillar, Bobst, and Mercuri Urval, in which he held various senior positions, most recently as Head of Human resources of the Bobst Group, based in Switzerland. He also contributed to the development of his family company in the areas of cosmetics, healthcare and wellness. Mr. Kairouz joined Debiopharm in January 2010 as Director of Human Resources for Debiopharm SA and for Debiopharm Group™.
 |
Alexandre MaretDirector Finance and Administration, Debiopharm SA |
Mr Maret received his Enterprise Economist diploma from the University of Applied Sciences, Western Switzerland (HES SO) in 1996. He has acquired an extensive experience in the accounting services of several companies (bank, international fiduciary, e-business). He joined Debiopharm in 2005.
 |
David DeperthesDirector Business Development & Licensing, Debiopharm SA |
